Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$28.25 USD
-0.04 (-0.14%)
Updated May 6, 2024 04:00 PM ET
After-Market: $28.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.25 USD
-0.04 (-0.14%)
Updated May 6, 2024 04:00 PM ET
After-Market: $28.27 +0.02 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
Understanding Dentsply (XRAY) Reliance on International Revenue
by Zacks Equity Research
Evaluate Dentsply's (XRAY) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.
Here's What Key Metrics Tell Us About Dentsply (XRAY) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Dentsply (XRAY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Dentsply International (XRAY) Meets Q1 Earnings Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 0% and 1.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Zacks Equity Research
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.
Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Dentsply International (XRAY) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Here's Why Dentsply International (XRAY) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Dentsply International (XRAY) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Dentsply International (XRAY) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Dentsply (XRAY) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.
Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dentsply (XRAY) delivered earnings and revenue surprises of 2.33% and 4.50%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 5.19% and 1.72%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Stay Ahead of the Game With Dentsply (XRAY) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Dentsply (XRAY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.
Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.
Will Dentsply (XRAY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.